Apellis Pharmaceuticals, Inc(NASDAQ:APLS) 
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials fo...
Website: http://www.apellis.com
Founded: 2009
Full Time Employees: 350
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 22.57
H 23.10
L 19.75
C 19.97
V 3,491,118
10EMA 19.97
20EMA 19.97
60EMA 19.97
120EMA 19.97
250EMA 19.97